THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT – EXCLUSIVE COVER PAGEPatent License Agreement • May 12th, 2022 • 2seventy Bio, Inc. • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
NATIONAL INSTITUTES OF HEALTH 1st AMENDMENT TO [***] [***] No.: [***]2seventy Bio, Inc. • May 12th, 2022 • Pharmaceutical preparations
This is the first amendment (“First Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and 2seventy bio, Inc. having an effective date of 31 August 2015 and having NIH Reference Number [***] (“Agreement”). This First Amendment, having NIH Reference Number [***], is made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and 2seventy bio, Inc. having an office at 60 Binney St., Cambridge, MA 02142 (the “Licensee”). This First Amendment includes, in addition to the amendments made below, 1) a Signature Page, and 2) Attachment 1 (Royalty Payment Information).
